REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail tested for aggressive lymphomas
Disease control OngoingThis early-stage study is testing a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in patients whose B-cell non-Hodgkin lymphoma has come back or hasn't responded to previous treatments. The main goal is to find the safest and most effective dose of the dru…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated Apr 01, 2026 18:41 UTC
-
New drug duo aims to tame resistant blood cancers
Disease control OngoingThis study is testing the safety and effectiveness of combining two existing drugs, nivolumab and lenalidomide, for patients with non-Hodgkin or Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal is to see if using these drugs together can bet…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Three-Pronged attack tested against tough blood cancer
Disease control TerminatedThis study aimed to test whether combining three drugs—rituximab, venetoclax, and bortezomib—could help control an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to standard treatments. The trial was designed …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for patients when CAR-T fails: immunotherapy trial targets stubborn blood cancers
Disease control OngoingThis study is testing whether the immunotherapy drug nivolumab can help control blood cancers that have returned, stopped responding, or are still detectable after a patient has already received CAR-T cell therapy. It is for adults with specific types of lymphoma, leukemia, or mu…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Tracking a new lymphoma Drug's Real-World performance
Disease control OngoingThis study is observing how well the drug epcoritamab works for patients with an aggressive type of lymphoma (DLBCL) that has returned or stopped responding to other treatments. It follows 150 patients in Italy who are already receiving the drug through a special access program, …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Sponsor: Andrés José Maria Ferreri • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug combo tested for Tough-to-Treat blood cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug, pevonedistat, when given with an existing drug, ibrutinib. It is for adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal i…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Double-Target CAR-T cells tested in fight against tough blood cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a new type of CAR-T cell therapy designed to attack two common proteins (CD19 and CD20) found on certain blood cancer cells. The therapy involves collecting a patient's own immune cells, modifying them in a lab to reco…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo aims to tame Tough-to-Treat lymphoma
Disease control OngoingThis study is for adults whose aggressive lymphoma has returned or not responded to prior treatment. It compares a new two-drug combination (loncastuximab tesirine plus rituximab) against standard immunochemotherapy. The main goal is to see which treatment better delays the cance…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Major trial tests new drug combo for Tough-to-Treat blood cancer
Disease control OngoingThis large, international Phase 3 study is testing whether adding a newer drug called polatuzumab vedotin to a standard chemotherapy combination (R-ICE) works better for controlling aggressive lymphoma that has come back or didn't respond to first treatment. About 306 adults with…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New hope for Tough-to-Treat lymphoma: early trial tests powerful drug cocktail
Disease control OngoingThis early-stage study is testing a new combination of drugs for patients with an aggressive type of lymphoma (DLBCL) that has returned or not responded to previous treatment. Researchers are adding a drug called carfilzomib to a standard chemotherapy regimen to see if it's safe,…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Early trial tests new Two-Drug attack on Tough-to-Treat blood cancers
Disease control OngoingThis early-stage study is testing a combination of two drugs, pembrolizumab and vorinostat, for patients with certain types of lymphoma that have come back or stopped responding to previous treatments. The main goals are to find the safest dose and understand the side effects of …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Scientists test new drug duo in fight against stubborn lymphoma
Disease control OngoingThis early-stage study is testing the safety and best dose of two drugs, ibrutinib and lenalidomide, when given together. It is for adults whose B-cell non-Hodgkin lymphoma has come back or has not responded to previous treatments. The goal is to see if combining these drugs is s…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New immune attack on tough cancers: can a combo drug beat the odds?
Disease control OngoingThis study is testing whether adding a new immunotherapy drug (varlilumab) to an existing one (nivolumab) works better than nivolumab alone for patients with aggressive B-cell lymphomas that have come back or stopped responding to standard treatments. The goal is to see if the tw…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Scientists test new drug duo in fight against Tough-to-Treat blood cancer
Disease control OngoingThis study is testing whether combining two existing cancer drugs, copanlisib and venetoclax, can help control an aggressive type of lymphoma called DLBCL that has returned or stopped responding to other treatments. The first part of the study aims to find a safe dose, and the se…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Boosting the immune System's cancer fighters: new combo therapy tested for tough lymphomas
Disease control OngoingThis early-stage trial is testing whether adding an investigational drug called NKTR-255 to an approved CAR-T cell therapy makes the treatment more effective for adults with large B-cell lymphoma that has returned or not responded to prior treatments. NKTR-255 is designed to boos…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
Early trial launches Four-Pronged attack on Tough-to-Treat blood cancer
Disease control OngoingThis early-stage study is testing a new four-drug combination for a very aggressive type of lymphoma that has returned or stopped responding to standard treatments. The goal is to see if combining an immunotherapy drug (atezolizumab) with two chemotherapy drugs and a targeted ant…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC
-
New hope for patients Who've run out of options: experimental drug enters human testing
Disease control OngoingThis early-stage study is testing a new oral drug called BGB-21447 in adults with certain advanced blood cancers that have returned or stopped responding to other treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also loo…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC
-
Targeted attack on stubborn lymphoma shows promise
Disease control OngoingThis study is testing a new combination of drugs for people with an aggressive type of lymphoma that has returned or not responded to the first treatment. The treatment combines a targeted antibody-drug with standard chemotherapy and immunotherapy. The goal is to see if this comb…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 09, 2026 14:23 UTC
-
New 'Living Drug' trial offers hope for patients with aggressive lymphoma
Disease control OngoingThis study is testing a new type of personalized cell therapy for patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them to better tar…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC